Profound Medical Corp.

Good day, and thank you for standing by. Welcome to the Profound Medical Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Stephan Kilmer, Investor Relations. Please go ahead.

Stephan Kilmer Thank you.

Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the United States and Canada. All forward-looking statements are based on profound current beliefs, assumptions, and expectations, and relate to, among other things, any expressed or implied statements or guidance regarding current or future financial performance and position, including the company's year 2024 financial outlook and related assumptions, the expectations regarding the efficacy of profound technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain, and osteoid osteoma, and its future revenues and financial results. Such statements involve unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than is required by law. Representing the company today are Dr. Arun Manawat, Profound's Chief Executive Officer, Rashed Dhawan, the company's Chief Financial Officer, and Dr. Matthew Burtnick, Profound's President. With that said, I'll now turn the call over to Rashed.